Covered recipient · General Payments record
ANGELA L RUSH
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,311.28
- Reported across 62 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $586.26 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $136.81 | 4 |
| ARGENX US, INC. | $124.28 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $119.32 | 1 |
| ABBVIE INC. | $58.22 | 2 |
| UCB, Inc. | $43.38 | 2 |
| EISAI INC. | $28.88 | 1 |
| Otsuka America Pharmaceutical, Inc. | $21.66 | 1 |
| GE HEALTHCARE | $19.46 | 1 |
| Alexion Pharmaceuticals, Inc. | $17.21 | 1 |
| Biogen, Inc. | $17.04 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $31.81 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108125947 | CMS |
| ABBVIE INC. | $26.41 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108125949 | CMS |
| Alexion Pharmaceuticals, Inc. | $17.21 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093954258 | CMS |
| ARGENX US, INC. | $17.97 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142146261 | CMS |
| ARGENX US, INC. | $106.31 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142148812 | CMS |
| Biogen, Inc. | $17.04 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104829938 | CMS |
| Eisai Inc. | $28.88 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110793257 | CMS |
| GE HEALTHCARE | $19.46 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144683560 | CMS |
| Lilly USA, LLC | $15.13 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135472055 | CMS |
| Lilly USA, LLC | $15.73 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135533988 | CMS |
| Lilly USA, LLC | $19.20 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135511759 | CMS |
| Lilly USA, LLC | $86.75 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135501550 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.66 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119176724 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $119.32 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137817933 | CMS |
| UCB, Inc. | $23.03 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143294710 | CMS |
| UCB, Inc. | $20.35 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143294715 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2024
- Source files
- Dataset page · Bulk file · PY2021 , PY2022 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.